2 ms·
The article was heavy on the free research aspect, but light on the commercial application. I'm curious about the business strategy. Does Google intend to lice
by s1artibartfast 3y ago
The article was heavy on the free research aspect, but light on the commercial application.
I'm curious about the business strategy. Does Google intend to license out tools, partner, or consult for commercial partners?
- ilrwbwrkhv 3y agoas soon as google tries to think commercially this will shut down so the longer it stays pure research the better. google is bad with productization.
- s1artibartfast 3y agoI don't think it was ever pure research. The article talks about infinity labs, which is the co. Mercial branch for drug discovery. I do agree that Google seems bad at commercialization, which is why I'm curious on what the strategy is. It is hard to see them being paid consultants or effective partners for pharma companies, let alone developing drugs themselves.
- throwtappedmac 3y ago[flagged]
- candiodari 3y agoI wonder what the license for RoseTTAFold is. On github you have: https://github.com/RosettaCommons/RoseTTAFold/blob/main/LICENSE https://github.com/RosettaCommons/RoseTTAFold/blob/main/LICE... But there's also: https://files.ipd.uw.edu/pub/RoseTTAFold/Rosetta-DL_LICENSE.txt https://files.ipd.uw.edu/pub/RoseTTAFold/Rosetta-DL_LICENSE.... Which is it?
- a_bonobo 3y agoThis version has Isomorphic Labs far more in the focus of the press release, which seems to be now the commercial arm more or less licensing access out. The new AlphaFold server does not do everything the paper says AlphaFold 3 says it does. You cannot predict docking with the server! That is the main interest of pharma companies, 'does our medication bind to the target protein?'. From the FAQ: 'AlphaFold Server is a web-service that offers customized biomolecular structure prediction. It makes several newer AlphaFold3 capabilities available, including support for a wider range of molecule type' - that's not ALL AlphaFold3 capabilities. Isomorphic prints the money with those additional capabilities. It's hilarious that Google says they don't allow this for safety reasons, pure OpenAI fluff. It's just money.